ADR-002K cell treatment for heart failure from ischemic heart disease during bypass surgery
Tests ADR-002K in people with ischemic heart disease and heart failure having bypass surgery.
Plain-language title generated from the registry record
Registry title: Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG
Key facts
- Where
- Osaka, JapanSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07192211, who can take part
Where in Japan
- The University of Osaka HospitalOsaka, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rohto Pharmaceutical Co., Ltd.
- Trial code
- NCT07192211
- Record updated
- 9 June 2026
- Original description
ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.Read full original descriptionShow less
Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo Coronary Artery Bypass Surgery
ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.
Inclusion: Patients clinically diagnosed with chronic heart failure due to ischemic heart disease who undergo CABG; Patients with an LVEF of less than 40% as determined by the cardiac ultrasound at the screening examination; Others.
Exclusion: Patients who have developed acute coronary syndrome within 3 months prior to obtaining consent; Patients who have a combination of cardiovascular disease such as severe organic valvular disease; Others.